Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?
Asselah, T; Marcellin, P; Schinazi, R F.
Liver International 38: 7-13
2018
ISSN/ISBN: 1478-3223 DOI: 10.1111/liv.13673
Accession: 065143441
Around 71 million people are chronically infected with Hcv worldwide. Hcv antiviral drug development has been remarkable. The availability of pangenotypic direct-acting antivirals with excellent efficacy and good tolerability profiles offer a unique opportunity to achieve Hcv elimination worldwide. IFN-free Daa combinations can now cure Hcv in more than 95% of patients with Hcv infection after 8-12 weeks of treatment.
PDF emailed within 0-6 h: $19.90
Related References
Asselah, T.; Marcellin, P.; Schinazi, R.F. 2018: Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure? Liver International: Official Journal of the International Association for the Study of the Liver 38(Suppl 1): 7-13Kanda, T.; Nakamoto, S.; Nakamura, M.; Jiang, X.; Miyamura, T.; Wu, S.; Yokosuka, O. 2014: Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection Journal of Clinical and Translational Hepatology 2(1): 1-6
Welsch, C.; Jesudian, A.; Zeuzem, S.; Jacobson, I. 2012: New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives Gut 61(Suppl 1): I36-I46
Zanaga, L.P.; Miotto, N.; Mendes, L.C.; Stucchi, R.S.B.; Vigani, A.G. 2016: Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents Brazilian Journal of Medical and Biological Research 49(11): E5504
Mauge, L.; Pavie, J.; Batisse, D.; Darnige, L. 2018: Acquired hemophilia a resolution in a hepatitis C virus/human immunodeficiency virus-coinfected patient with cure of hepatitis C by direct-acting antiviral agents Hepatology 67(2): 794-796
Bernstein, D.E. 2015: Roadblocks to Accessing Direct-Acting Antiviral Agents for Treatment of Hepatitis C Virus Infection Gastroenterology and Hepatology 11(5): 331-333
Fernández-Yunquera, A.; Rincón, D.; Salcedo, M.; Bañares, R. 2013: Update on the use of direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection Revista Espanola de Quimioterapia: Publicacion Oficial de la Sociedad Espanola de Quimioterapia 26(3): 189-192
Alghamdi, A.S.; Alqutub, A.; Abaalkhail, F.; Sanai, F.M.; Alghamdi, H.; Altraif, I.; Alswat, K.A.; Alghamdi, M.Y.; Babatin, M.A.; Alfaleh, F.Z. 2015: SASLT position statement on the direct-acting antiviral agents for the treatment of hepatitis C virus infection Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association 21(2): 60-63
Xia, Y.; Liang, T.J. 2019: Development of Direct-acting Antiviral and Host-targeting Agents for Treatment of Hepatitis B Virus Infection Gastroenterology 156(2): 311-324
Quer, J.; Buti, M.; Cubero, M.; Guardia, J.; Esteban, R.; Esteban, J.I. 2010: New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents Infection and Drug Resistance 3: 133-145
Yang, J.; Rao, H.Y. 2018: Effectiveness and safety of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection Zhonghua Gan Zang Bing Za Zhi 26(3): 175-178
Goel, A.; Bhargava, R.; Rai, P.; Aggarwal, R. 2017: Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience Indian Journal of Gastroenterology: Official Journal of the Indian Society of Gastroenterology 36(3): 227-234
Wang, Y.; Hu, Y.; Zhang, X.; Luo, Y.; Ma, L.; Lu, J.; Liang, Q.; Xu, C.; Zhao, C.; Pan, C.Q. 2022: IP-10 Interferes with the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection Frontiers in Public Health 10: 911551
Maan, R.; van Tilborg, M.; Deterding, K.; Ramji, A.; van der Meer, A.J.; Wong, F.; Fung, S.; Sherman, M.; Manns, M.P.; Cornberg, M.; Hansen, B.E.; Wedemeyer, H.; Janssen, H.L.A.; de Knegt, R.J.; Feld, J.J. 2016: Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients with Chronic Hepatitis C Virus Infection and Cirrhosis Clinical Gastroenterology and Hepatology: the Official Clinical Practice Journal of the American Gastroenterological Association 14(12): 1821-1830.E6
Boglione, L.; Mornese Pinna, S.; De Nicolò, A.; Cusato, J.; Cariti, G.; Di Perri, G.; D'Avolio, A. 2017: Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: a prospective study Journal of Viral Hepatitis 24(10): 850-857
Francis, A.K.; Beaudoin, F.L.; Naidjate, S.S.; Berard-Collins, C.; Zullo, A.R. 2020: Comparing Treatment Response Between Older and Younger Patients with Chronic Hepatitis C Virus Infection on Direct-acting Antiviral Agents Rhode Island Medical Journal 103(5): 35-40
Mei, Y.-Y.; Chen, Y.-M.; Wu, Y.-K.; Zhang, X.-H.; Xu, W.-X. 2020: Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection Canadian Journal of Gastroenterology and Hepatology 2020: 8872120
Ambarsari, C.G.; Hidayati, E.L.; Hasan, I.; Grace, A.; Oswari, H. 2020: Successful Treatment of Hepatitis C Virus Infection Using Direct-Acting Antiviral Agents (DAAs) in Adolescents with Kidney Transplantation: a Case Series International Journal of Nephrology and Renovascular Disease 13: 139-146
Kiser, J.J.; Flexner, C. 2013: Direct-acting antiviral agents for hepatitis C virus infection Annual Review of Pharmacology and Toxicology 53: 427-449
Liu, C.-H.; Liu, C.-J.; Su, T.-H.; Fang, Y.-J.; Yang, H.-C.; Chen, P.-J.; Chen, D.-S.; Kao, J.-H. 2017: Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection Open Forum Infectious Diseases 4(1): Ofx028